{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:04:32Z","timestamp":1790064272782,"version":"4.0.1"},"reference-count":100,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Thyroid-Stimulating Hormone (TSH) suppression therapy is a key strategy in managing differentiated thyroid cancer (DTC) after surgery, but its clinical use has long faced the challenge of a \u201cone-size-fits-all\u201d approach. Previous studies mainly focus on balancing risks and benefits, yet the process of individualized decision-making still lacks systematic integration and synthesis. This article offers a comprehensive review of this issue from an individualized perspective. Mechanistically, it details the networked regulatory mechanisms by which TSH promotes the proliferation, invasion, and dedifferentiation of thyroid cancer cells through the activation of signaling pathways like G\u03b1s and G\u03b1q\/11 via TSHR. It also uncovers the complex relationship where TSH collaborates with the key oncogenic drivers to advance tumor growth and the loss of oncogene-induced senescence after long-term stimulation. Clinically, we develop an individualized decision-making framework based on three dimensions: patient factors, tumor traits, and treatment process. Additionally, we synthesize existing evidence to define the benefit boundaries of TSH suppression, aiming to guide clinical practice.<\/jats:p>","DOI":"10.3389\/fendo.2026.1842060","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:48:22Z","timestamp":1783403302000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["TSH suppression therapy from an individualized perspective: from mechanism to clinical decision-making"],"prefix":"10.3389","volume":"17","author":[{"given":"Zhaoqing","family":"Li","sequence":"first","affiliation":[{"name":"Department of Thyroid Surgery, General Surgery Center, The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tengfei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Thyroid Surgery, General Surgery Center, The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.26348","article-title":"Thyroid cancer a review","volume":"331","author":"Boucai","year":"2024","journal-title":"Jama"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.18.2164","article-title":"Increasing incidence of thyroid cancer in the United States, 1973-2002","volume":"295","author":"Davies","year":"2006","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.2719","article-title":"Trends in thyroid cancer incidence and mortality in the United States, 1974-2013","volume":"317","author":"Lim","year":"2017","journal-title":"Jama"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2022.5045","article-title":"Association of treatment strategies and tumor characteristics with overall survival among patients with anaplastic thyroid cancer","volume":"149","author":"Shannon","year":"2023","journal-title":"JAMA Otolaryngology\u2013Head Neck Surg"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32041","article-title":"Anti\u2010PD\u20101\/PD\u2010L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer","volume":"144","author":"Gunda","year":"2019","journal-title":"Int J Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0296-2","article-title":"Combinations of BRAF inhibitor and anti-PD-1\/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer","volume":"119","author":"Gunda","year":"2018","journal-title":"Br J Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1177\/10507256251363120","article-title":"2025 American Thyroid Association management guidelines for adult patients with differentiated thyroid cancer","volume":"35","author":"Ringel","year":"2025","journal-title":"Thyroid\u00ae"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-020-00448-z","article-title":"Current practice in patients with differentiated thyroid cancer","volume":"17","author":"Schlumberger","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-2566","article-title":"Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer","volume":"92","author":"Hovens","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s12020-019-02051-3","article-title":"Thyroid hormone therapy in differentiated thyroid cancer","volume":"66","author":"Grani","year":"2019","journal-title":"Endocrine"},{"key":"B12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/ncpendmet0020","article-title":"Thyroid-hormone therapy and thyroid cancer: a reassessment","volume":"1","author":"Biondi","year":"2005","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-42-2-395","article-title":"Presence of TSH receptor in thyroid neoplasms","volume":"42","author":"Ichikawa","year":"1976","journal-title":"J Clin Endocrinol Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1997.431","article-title":"Relationship between prognostic score and thyrotropin receptor (TSH-R) in papillary thyroid carcinoma immunohistochemical detection of TSH-R","volume":"76","author":"Tanaka","year":"1997","journal-title":"Br Joumal Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2017.7122","article-title":"Downregulated expression of TSHR is associated with distant metastasis in thyroid cancer","volume":"14","author":"Liu","year":"2017","journal-title":"Oncol Lett"},{"key":"B16","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1530\/ey.18.3.1","article-title":"Radiation-related genomic profile of papillary thyroid carcinoma after the Chernobyl accident","volume":"372","author":"Morton","year":"2021","journal-title":"Science"},{"key":"B17","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1159\/000456576","article-title":"Molecular markers involved in tumorigenesis of thyroid carcinoma: Focus on aggressive histotypes","volume":"150","author":"Penna","year":"2016","journal-title":"Cytogene Genome Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1210\/er.2007-0007","article-title":"BRAF mutation in papillary thyroid cancer: Pathogenic role, molecular bases, and clinical implications","volume":"28","author":"Xing","year":"2007","journal-title":"Endocr Rev"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.801925","article-title":"Hashimoto\u2019s thyroiditis: A \u201cdouble-edged sword\u201d in thyroid carcinoma","volume":"13","author":"Xu","year":"2022","journal-title":"Front Endocrinol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.718578","article-title":"Crosstalk between abnormal TSHR signaling activation and PTEN\/PI3K in the dedifferentiation of thyroid cancer cells","volume":"11","author":"Feng","year":"2021","journal-title":"Front Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e004049","DOI":"10.1136\/jitc-2021-004049","article-title":"TSH-TSHR axis promotes tumor immune evasion","volume":"10","author":"Wu","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e240369","DOI":"10.1530\/etj-24-0369","article-title":"TSHR in thyroid cancer: Bridging biological insights to targeted strategies","volume":"14","author":"Xu","year":"2025","journal-title":"Eur Thyroid J"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1530\/erc-17-0010","article-title":"Targeting the TSH receptor in thyroid cancer","volume":"24","author":"Rowe","year":"2017","journal-title":"Endocrine-Related Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1210\/en.2008-0878","article-title":"Characterization of thyrotropin receptor antibody-induced signaling cascades","volume":"150","author":"Morshed","year":"2009","journal-title":"Endocrinology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/ng0794-396","article-title":"Germline mutations in the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperthyroidism","volume":"7","author":"Duprez","year":"1994","journal-title":"Nat Genet"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1515\/enr-2017-0012","article-title":"The role of thyrostimulin and its potential clinical significance","volume":"51","author":"K","year":"2017","journal-title":"Endocrine Regulations"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/cells9071730","article-title":"The molecular function and clinical role of thyroid stimulating hormone receptor in cancer cells","volume":"9","author":"Chu","year":"2020","journal-title":"Cells-Basel"},{"key":"B28","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/35085068","article-title":"Transcriptional regulation by the phosphorylation-dependent factor CREB","volume":"2","author":"Mayr","year":"2001","journal-title":"Mol Cell Biol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2025-1311","article-title":"Abstract 1311: CREB-driven tumor cell invasion and ECM remodeling promote metastasis","volume":"85","author":"Jinka","year":"2025","journal-title":"Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2025.101660","article-title":"CREB fuels tumorigenesis in alcoholic pancreatitis","volume":"20","author":"Sardarni","year":"2026","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2020.0297","article-title":"A positive feedback loop between DICER1 and differentiation transcription factors is important for thyroid tumorigenesis","volume":"31","author":"Ram\u00edrez-Moya","year":"2021","journal-title":"Thyroid\u00ae"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e2208749120","DOI":"10.1073\/pnas.2208749120","article-title":"Soluble cyclase-mediated nuclear cAMP synthesis is sufficient for cell proliferation","volume":"20","author":"Pizzoni","year":"2023","journal-title":"Proc Natl Acad Sci"},{"key":"B33","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s12943-022-01658-x","article-title":"CREB3L1 promotes tumor growth and metastasis of anaplastic thyroid carcinoma by remodeling the tumor microenvironment","volume":"21","author":"Pan","year":"2022","journal-title":"Mol Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e5395","DOI":"10.1371\/journal.pone.0005395","article-title":"CD133+ anaplastic thyroid cancer cells initiate tumors in immunodeficient mice and are regulated by thyrotropin","volume":"4","author":"Friedman","year":"2009","journal-title":"PloS One"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1530\/joe-17-0266","article-title":"Key signaling pathways in thyroid cancer","volume":"235","author":"Zaballos","year":"2017","journal-title":"J Endocrinol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-023-00598-y","article-title":"Pathogenesis of cancers derived from thyroid follicular cells","volume":"23","author":"Fagin","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40291-015-0175-y","article-title":"PI3K\/AKT pathway and its mediators in thyroid carcinomas","volume":"20","author":"Nozhat","year":"2015","journal-title":"Mol Diagnosis Ther"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2014.10.005","article-title":"TSH signaling overcomes B-RafV600E\u2013induced senescence in papillary thyroid carcinogenesis through regulation of DUSP6","volume":"16","author":"Kim","year":"2014","journal-title":"Neoplasia"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.31083\/fbl39100","article-title":"Targeting Akt signaling pathway in cancer: Molecular mechanisms and advances in therapeutic interventions","volume":"30","author":"Leiphrakpam","year":"2025","journal-title":"Front Bioscience-Landmark"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2015.253","article-title":"TSH overcomes BrafV600E-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer","volume":"35","author":"Zou","year":"2015","journal-title":"Oncogene"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-3997","article-title":"Hypothyroidism following hemithyroidectomy: Incidence, risk factors, and clinical characteristics","volume":"101","author":"Ahn","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B42","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12893-024-02426-y","article-title":"Factors influencing TSH suppression efficacy in postoperative papillary thyroid carcinoma patients: A retrospective cohort study","volume":"24","author":"Zhang","year":"2024","journal-title":"BMC Surg"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-007-0513-8","article-title":"Prediction of hypothyroidism after hemithyroidectomy: A biochemical and pathological analysis","volume":"265","author":"Koh","year":"2007","journal-title":"Eur Arch Oto-Rhino-Laryngol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-019-00711-7","article-title":"Age-related resistance to thyroid hormone action","volume":"36","author":"Mooradian","year":"2019","journal-title":"Drug Aging"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.4158\/ep09257.or","article-title":"Sex and age differences in levothyroxine dosage requirement","volume":"16","author":"Jonklaas","year":"2010","journal-title":"Endocrine Pract"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00520","article-title":"Thyroid hormone supplementation therapy for differentiated thyroid cancer after lobectomy: 5 years of follow-up","volume":"11","author":"Kim","year":"2020","journal-title":"Front Endocrinol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2006.16.583","article-title":"The effects of thyrotropin-suppressive therapy on bone metabolism in patients with well-differentiated thyroid carcinoma","volume":"16","author":"Heemstra","year":"2006","journal-title":"Thyroid"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1089\/105072503321669839","article-title":"Bone metabolism in patients with differentiated thyroid carcinoma receiving suppressive levothyroxine treatment","volume":"13","author":"Mikosch","year":"2003","journal-title":"Thyroid"},{"key":"B49","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/cen.12560","article-title":"Volumetric bone mineral density and bone geometry assessed by peripheral quantitative computed tomography in women with differentiated thyroid cancer under TSH suppression","volume":"82","author":"Tournis","year":"2014","journal-title":"Clin Endocrinol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/s0003-4266(16)30014-2","article-title":"Risk-benefit ratio for TSH-suppressive levothyroxine therapy in differentiated thyroid cancer","volume":"76","author":"Cao","year":"2015","journal-title":"Annales d'Endocrinol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra1901214","article-title":"Drug effects on the thyroid","volume":"381","author":"Burch","year":"2019","journal-title":"N Engl J Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1210\/er.2018-00119","article-title":"Interferences with thyroid function immunoassays: Clinical implications and detection algorithm","volume":"39","author":"Favresse","year":"2018","journal-title":"Endocr Rev"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1097\/med.0000000000000558","article-title":"Alternative routes of levothyroxine administration for hypothyroidism","volume":"27","author":"Ritter","year":"2020","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2012.0435","article-title":"Serum thyrotropin levels following levothyroxine administration at breakfast","volume":"23","author":"Perez","year":"2013","journal-title":"Thyroid"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(54)91480-4","article-title":"Metastatic carcinoma of the thyroid successfully treated with thyroxine","volume":"263","author":"Balme","year":"1954","journal-title":"Lancet"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-197705000-00001","article-title":"Papillary thyroid carcinoma a 10 year follow-up report of the impact of therapy in 576 patients","volume":"70","author":"Mazzaferri","year":"1980","journal-title":"Am J Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1080\/078538902321117760","article-title":"Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer","volume":"34","author":"McGriff","year":"2002","journal-title":"Ann Med"},{"key":"B58","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1530\/erc-21-0403","article-title":"Effect of TSH levels during active surveillance of PTMC according to age","volume":"29","author":"Kim","year":"2022","journal-title":"Endocr Relat Cancer"},{"key":"B59","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1007\/978-3-032-13130-0_6","article-title":"Thyroid-stimulating hormone, age, and tumor size are risk factors for progression during active surveillance of low-risk papillary thyroid microcarcinoma in adults","volume":"47","author":"Ito","year":"2023","journal-title":"World J Surg"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-013-2335-8","article-title":"Association between serum thyrotropin concentration and growth of asymptomatic papillary thyroid microcarcinoma","volume":"38","author":"Sugitani","year":"2014","journal-title":"World J Surg"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.7754","article-title":"Association of thyrotropin suppression with survival outcomes in patients with intermediate- and high-risk differentiated thyroid cancer","volume":"2","author":"Klubo-Gwiezdzinska","year":"2019","journal-title":"JAMA Netw Open"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2021.0404","article-title":"Optimal serum thyrotropin level for patients with papillary thyroid carcinoma after lobectomy","volume":"32","author":"Xu","year":"2022","journal-title":"Thyroid"},{"key":"B63","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1515\/fco-2015-0010","article-title":"The efficacy of thyrotropin suppression therapy in treatment of differentiated thyroid cancer after total thyroidectomy","volume":"6","author":"Abo-Touk","year":"2015","journal-title":"Forum Clin Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2011.04272.x","article-title":"Impact of moderate vs stringent TSH suppression on survival in advanced differentiated thyroid carcinoma","volume":"76","author":"Diessl","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1089\/thy.1998.8.737","article-title":"Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry","volume":"8","author":"Cooper","year":"1998","journal-title":"Thyroid"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2006.16.1229","article-title":"Outcomes of patients with differentiated thyroid carcinoma following initial therapy","volume":"16","author":"Jonklaas","year":"2006","journal-title":"Thyroid"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1346","article-title":"Long-term outcomes following therapy in differentiated thyroid carcinoma: NTCTCS registry analysis 1987\u20132012","volume":"100","author":"Carhill","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.49.1043","article-title":"Long-term cardiovascular mortality in patients with differentiated thyroid carcinoma: an observational study","volume":"31","author":"Hesselink","year":"2013","journal-title":"J Clin Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.112.096024","article-title":"Subclinical thyroid dysfunction and the risk of heart failure events","volume":"126","author":"Gencer","year":"2012","journal-title":"Circulation"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e7895","article-title":"The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study","volume":"345","author":"Selmer","year":"2012","journal-title":"BMJ"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.25011\/cim.v35i3.16591","article-title":"Prevalence of atrial fibrillation in patients taking TSH suppression therapy for management of thyroid cancer","volume":"35","author":"Abonowara","year":"2012","journal-title":"Clin Invest Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.991876","article-title":"Meta-analysis of TSH suppression therapy and the risk of cardiovascular events after thyroid cancer surgery","volume":"13","author":"Yang","year":"2022","journal-title":"Front Endocrinol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1210\/jc.77.2.334","article-title":"Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine","volume":"77","author":"Biondi","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2010.0319","article-title":"Both exogenous subclinical hyperthyroidism and short-term overt hypothyroidism affect myocardial strain in patients with differentiated thyroid carcinoma","volume":"21","author":"Abdulrahman","year":"2011","journal-title":"Thyroid"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1210\/jc.81.12.4224","article-title":"Impaired cardiac reserve and exercise capacity in patients receiving long-term thyrotropin suppressive therapy with levothyroxine","volume":"81","author":"Biondi","year":""},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2018.1","article-title":"Balancing benefit and risk in TSH management of DTC","volume":"14","author":"Verburg","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"45","DOI":"10.11005\/jbm.2019.26.1.45","article-title":"Risk of osteoporotic fractures after thyroid-stimulating hormone suppression therapy in patients with thyroid cancer","volume":"26","author":"Lee","year":"2019","journal-title":"J Bone Metab"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2014.0287","article-title":"Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma","volume":"25","author":"Wang","year":"2015","journal-title":"Thyroid"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2011.09.013","article-title":"Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled study","volume":"150","author":"Sugitani","year":"2011","journal-title":"Surgery"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0234","article-title":"Risk of osteoporosis and fractures in patients with thyroid cancer: a case-control study in U.S. veterans","volume":"24","author":"Papaleontiou","year":"2019","journal-title":"Oncologist"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.769074","article-title":"Effect of thyroid-stimulating hormone suppression on muscle function after total thyroidectomy in patients with thyroid cancer","volume":"12","author":"Lee","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B82","doi-asserted-by":"publisher","first-page":"d2238","DOI":"10.1007\/978-1-4419-1005-9_101139","article-title":"Levothyroxine dose and risk of fractures in older adults nested case-control study","volume":"342","author":"Turner","year":"2011","journal-title":"BMJ"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2014.10.009","article-title":"The effects of thyrotropin-suppressing therapy on bone metabolism in patients with well-differentiated thyroid carcinoma","volume":"71","author":"Kim","year":"2015","journal-title":"Bone"},{"key":"B84","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1210\/jc.2016-2740","article-title":"The effect of TSH-suppression on vertebral trabecular bone scores in patients with differentiated thyroid carcinoma","volume":"108","author":"Moon","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2023.5619","article-title":"Endogenous and exogenous thyrotoxicosis and risk of incident cognitive disorders in older adults","volume":"183","author":"Adams","year":"2023","journal-title":"JAMA Intern Med"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2008.01.1311","article-title":"Cognitive functions and mood during chronic thyrotropin-suppressive therapy with L-thyroxine in patients with differentiated thyroid carcinoma","volume":"35","author":"Jaracz","year":"2012","journal-title":"J Endocrinol Invest"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-3686","article-title":"The effects of levothyroxine replacement or suppressive therapy on health status, mood, and cognition","volume":"99","author":"Samuels","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-4454","article-title":"The effect of long-term thyroid-stimulating hormone suppressive therapy on the cognitive function of elderly patients with differentiated thyroid carcinoma","volume":"99","author":"Moon","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1677\/erc.0.0100601","article-title":"Quality of life and psychometric functionality in patients with differentiated thyroid carcinoma","volume":"10","author":"Botella-Carretero","year":"2003","journal-title":"Endocrine-Related Cancer"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.02047","article-title":"Health-related quality of life, anxiety and depression in thyroid cancer patients under short-term hypothyroidism and TSH-suppressive levothyroxine treatment","volume":"153","author":"Tagay","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-021-02786-y","article-title":"Distress, anxiety, depression and unmet needs in thyroid cancer survivors: a longitudinal study","volume":"74","author":"Dionisi-Vici","year":"2021","journal-title":"Endocrine"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2006.02458.x","article-title":"Quality of life in longterm exogenous subclinical hyperthyroidism and the effects of restoration of euthyroidism, a randomized controlled trial","volume":"64","author":"Eustatia\u2010Rutten","year":"2006","journal-title":"Clin Endocrinol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2018.0388","article-title":"Fear of recurrence and view of life affect health-related quality of life in patients with differentiated thyroid carcinoma: a prospective Swedish population-based study","volume":"28","author":"Hedman","year":"2018","journal-title":"Thyroid"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1590\/0004-2730000002968","article-title":"Exercise is associated with better quality of life in patients on TSH-suppressive therapy with levothyroxine for differentiated thyroid carcinoma","volume":"58","author":"Vig\u00e1rio","year":"2014","journal-title":"Arquivos Brasileiros Endocrinol Metabol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2018.10.008","article-title":"Thyroid hormone suppression therapy","volume":"48","author":"Biondi","year":"2019","journal-title":"Endocrinol Metab Clin North Am"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2024.0330","article-title":"Association between serum thyrotropin and cancer recurrence in differentiated thyroid cancer: a population-based retrospective cohort study","volume":"35","author":"Qiang","year":"2025","journal-title":"Thyroid"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.21037\/atm-20-4890","article-title":"Analysis of the strategy of LT4 prescribing and TSH monitoring for thyroid carcinoma after lobectomy","volume":"8","author":"Wang","year":"2020","journal-title":"Ann Transl Med"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2021.0617","article-title":"Optimal thyrotropin following lobectomy for papillary thyroid cancer: Does it exist","volume":"32","author":"Bischoff","year":"2022","journal-title":"Thyroid"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-023-03548-8","article-title":"Differentiated thyroid cancer: a focus on post-operative thyroid hormone replacement and thyrotropin suppression therapy","volume":"83","author":"Gigliotti","year":"2024","journal-title":"Endocrine"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2021.0033","article-title":"Thyrotropin suppression for papillary thyroid cancer: a physician survey study","volume":"31","author":"Papaleontiou","year":"2021","journal-title":"Thyroid"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1842060\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:48:23Z","timestamp":1783403303000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1842060\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":100,"alternative-id":["10.3389\/fendo.2026.1842060"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1842060","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"article-number":"1842060"}}